Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 11/20 | 0.53 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.52 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662457 | 0.87 | LTA4H (0.68) | LTA4HNPY5RALDH1A1GAA | |
| SCHEMBL5658771 | 0.85 | LTA4H (0.56) | LTA4HNPY5RALDH1A1GAA | |
| SCHEMBL5311089 | 0.79 | LTA4H (0.62) | LTA4HALDH1A1GAA | |
| SCHEMBL5656997 | 0.79 | LTA4H (0.62) | LTA4HMCHR1ALDH1A1GAA | |
| SCHEMBL5313799 | 0.79 | MAPT (0.62) | LTA4HALDH1A1 | |
| SCHEMBL5660589 | 0.78 | LTA4H (0.61) | LTA4HALDH1A1GAA | |
| SCHEMBL5662666 | 0.76 | LTA4H (0.56) | LTA4HNPY5RALDH1A1GAA | |
| SCHEMBL5312495 | 0.75 | LTA4H (0.74) | LTA4H | |
| SCHEMBL5373554 | 0.75 | LTA4H (0.57) | LTA4HNPY5RALDH1A1GAA | |
| SCHEMBL5661889 | 0.74 | LTA4H (0.85) | LTA4HNPY5RALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885MEP1A 2017/4885MEP1B 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.